December 8, 2025Blood

Visualizing systemic light chain amyloidosis with 18f-flutemetamol PET/CT: Correlation with biomarkers and clinical outcome

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis shows 97% visualization of systemic light chain amyloidosis using FMM PET/CT, suggesting impact on clinical outcomes.

FMM PET/CT visualized systemic involvement in 97% of patients with light chain amyloidosis, enhancing diagnostic capabilities.
Among 36 patients, positive cardiac uptake on PET/CT correlated significantly with NT-proBNP and troponin I values, indicating risk factors.
Computed tomography was employed along with FMM PET to identify organa involvement, yielding insights into patient prognosis.
Elevated NT-proBNP levels were strongly predictive of overall survival in patients, emphasizing the clinical relevance of biomarker monitoring.

Park et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows 97% visualization of systemic light chain amyloidosis using FMM PET/CT, suggesting impact on clinical outcomes.